Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.60 |
| ▸ | NEK2 | P51955 | 1/20 | 0.60 |
| ▸ | STK3 | Q13188 | 1/20 | 0.60 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.60 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13027398 | 0.94 | CHEK1 (0.62) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027461 | 0.91 | CHEK1 (0.60) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027437 | 0.88 | CHEK1 (0.66) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13028172 | 0.87 | CHEK1 (0.63) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027422 | 0.86 | CHEK1 (0.68) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027416 | 0.86 | CHEK1 (0.62) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027391 | 0.85 | CHEK1 (0.56) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027387 | 0.85 | CHEK1 (0.76) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027388 | 0.85 | CHEK1 (0.67) | CHEK1IRAK4JAK2ROCK2IGF1R | |
| SCHEMBL13027675 | 0.84 | CHEK1 (0.58) | CHEK1IRAK4JAK2ROCK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | CHEK1 113/4885IRAK4 525/4885JAK2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.